皮质类固醇与氯巴占治疗儿童睡眠期癫痫性电持续状态伴慢波激活的癫痫性脑病(RESCUE ESES):一项多中心随机对照试验
这项多中心随机对照试验比较皮质类固醇与氯巴占治疗儿童EE-SWAS后6个月的认知结局。45名儿童随机分组,因入组提前终止未达目标样本量。结果显示皮质类固醇组IQ改善应答率25% vs 氯巴占组0%(RR 10.0,95%CI 1.2-1310.4;p=0.025),认知总分应答率两组均为5%(RR 1.0,95%CI 0.1-11.7;p=0.97),不良事件发生率无差异。
要点
- 皮质类固醇组IQ改善≥11.25分者5/20(25%)vs 氯巴占组0/18(0%),RR 10.0(95%CI 1.2-1310.4;p=0.025)。
- 认知总分改善≥0.75分者皮质类固醇组1/22(5%)vs 氯巴占组1/21(5%),RR 1.0(95%CI 0.1-11.7;p=0.97)。
- 不良事件发生率两组无差异(RR 0.8,95%CI 0.4-1.4;p=0.65),无死亡报告。
核心结论
- 试验提前终止且未达到目标样本量,因此研究结果必须谨慎解读。
- 数据表明皮质类固醇相比氯巴占治疗在IQ结局上有改善,但认知总分未见差异。
- 研究结果强化了既往非对照研究的发现,支持对EE-SWAS儿童早期使用皮质类固醇。
研究设计与样本
- 多中心、随机对照试验,在7个欧洲国家的8个罕见癫痫三级转诊中心进行。
- 纳入标准为年龄2-12岁、纳入前6个月内诊断为EE-SWAS、既往未接受皮质类固醇或氯巴占治疗。
- 参与者按1:1随机分配至皮质类固醇组(口服泼尼松龙1-2 mg/kg/日连续治疗,或静脉注射甲泼尼龙20 mg/kg/日每4周连用3天脉冲治疗)或氯巴占组(口服0.5-1.2 mg/kg/日)。
- 主要结局为治疗6个月后的认知功能,通过IQ应答率(改善≥11.25 IQ分)或认知总分应答率(改善≥0.75分)评估。
- 因预定义的130名参与者入组被认定不可行,试验提前终止;最终45名儿童随机分组(皮质类固醇组n=22,氯巴占组n=23),氯巴占组2名儿童在6个月前退出并被排除在意向性治疗分析之外。
主要发现
- 2014年7月22日至2022年9月3日期间,45名儿童随机分配至皮质类固醇组(n=22)或氯巴占组(n=23)。
- 6个月评估时,IQ改善≥11.25分者皮质类固醇组5/20(25%)vs 氯巴占组0/18(0%)(RR 10.0,95%CI 1.2-1310.4;p=0.025)。
- 认知总分改善≥0.75分者皮质类固醇组1/22(5%)vs 氯巴占组1/21(5%)(RR 1.0,95%CI 0.1-11.7;p=0.97)。
- 不良事件发生于皮质类固醇组10/22(45%),最常见为体重增加;氯巴占组11/21(52%),最常见为疲劳和行为障碍;两组不良事件发生无差异(RR 0.8,95%CI 0.4-1.4;p=0.65)。
- 严重不良事件:皮质类固醇组1例(喉炎住院),氯巴占组2例(癫痫加重住院和呼吸道感染住院);无死亡报告。
关键数值与推荐
- IQ应答率定义为改善≥11.25 IQ分。
- 认知总分应答率定义为改善≥0.75分。
- 皮质类固醇方案:口服泼尼松龙1-2 mg/kg/日连续治疗,或静脉注射甲泼尼龙20 mg/kg/日每4周连用3天脉冲治疗。
- 氯巴占方案:口服0.5-1.2 mg/kg/日。
临床怎么用
- 作者认为研究结果强化了既往非对照研究的发现,支持对EE-SWAS儿童早期使用皮质类固醇。
局限性
- 试验提前终止,且未达到目标样本量(预定义130名参与者),因此研究结果必须谨慎解读。
- 氯巴占组2名儿童在6个月前退出并被排除在意向性治疗分析之外。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epileptic encephalopathy with spike-wave activation in sleep (EE-SWAS) is a rare syndrome associated with cognitive and behavioural regression. On the basis of mostly small observational and retrospective studies, corticosteroids and clobazam are often considered the most effective treatments for this syndrome. We aimed to compare cognitive outcomes of children with EE-SWAS 6 months after starting treatment with either corticosteroids or clobazam. METHODS: We did a multicentre, randomised controlled trial at eight tertiary referral centres for rare epilepsies in seven European countries. Children were eligible to participate if they were aged 2-12 years, were diagnosed with EE-SWAS within 6 months before inclusion, and had not been treated with corticosteroids or clobazam previously. Participants were randomly assigned (1:1) to treatment with corticosteroids (either continuous treatment with 1-2 mg/kg per day of prednisolone orally or pulse treatment with 20 mg/kg per day of methylprednisolone intravenously for 3 days every 4 weeks) or clobazam (0·5-1·2 mg/kg per day orally). The primary outcome was cognitive functioning after 6 months of treatment, which was assessed by either the intelligence quotient (IQ) responder rate (defined as improvement of ≥11·25 IQ points) or the cognitive sum score responder rate (defined as improvement of ≥0·75 points). Safety was assessed by number of adverse events and serious adverse events. Data were analysed in the intention-to-treat population, which included all children as randomised who had primary outcome data available at 6 months. The trial is registered with the Dutch Trial Register, Toetsingonline, NL43510.041.13, and the ISRCTN registry, ISRCTN42686094. The trial was terminated prematurely because enrolment of the predefined number of 130 participants was deemed not feasible. FINDINGS: Between July 22, 2014, and Sept 3, 2022, 45 children were randomly assigned to either corticosteroids (n=22) or clobazam (n=23); two children assigned clobazam dropped out before 6 months and were excluded from the intention-to-treat analysis. At the 6-month assessment, an improvement of 11·25 IQ points or greater was reported for five (25%) of 20 children assigned corticosteroids versus zero (0%) of 18 assigned clobazam (risk ratio [RR] 10·0, 95% CI 1·2-1310·4; p=0·025). An improvement of 0·75 points or more in the cognitive sum score was recorded for one (5%) of 22 children assigned corticosteroids versus one (5%) of 21 children assigned clobazam (RR 1·0, 95% CI 0·1-11·7, p=0·97). Adverse events occurred in ten (45%) of 22 children who received corticosteroids, most frequently weight gain, and in 11 (52%) of 21 children who received clobazam, most often fatigue and behavioural disturbances. Occurrence of adverse events did not differ between groups (RR 0·8, 95% CI 0·4-1·4; p=0·65). Serious adverse events occurred in one child in the corticosteroid group (hospitalisation due to laryngitis) and in two children in the clobazam group (hospitalisation due to seizure aggravation, and respiratory tract infection). No deaths were reported. INTERPRETATION: The trial was terminated prematurely, and the target sample size was not met, so our findings must be interpreted with caution. Our data indicated an improvement in IQ outcomes with corticosteroids compared with clobazam treatment, but no difference was seen in cognitive sum score. Our findings strengthen those from previous uncontrolled studies that support the early use of corticosteroids for children with EE-SWAS. FUNDING: EpilepsieNL, WKZ fund, European Clinical Research Infrastructure Network, and Ming fund.
引用
- van Arnhem MML, van den Munckhof B, Arzimanoglou A, et al. Corticosteroids versus clobazam for treatment of children with epileptic encephalopathy with spike-wave activation in sleep (RESCUE ESES): a multicentre randomised controlled trial. Lancet Neurol. 2023. PMID: 38081201. doi:10.1016/S1474-4422(23)00409-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。